PMID- 30214585
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 16
IP  - 4
DP  - 2018 Oct
TI  - Stereotactic body radiotherapy for centrally-located lung tumors with 56 Gy in 
      seven fractions: A retrospective study.
PG  - 4498-4506
LID - 10.3892/ol.2018.9188 [doi]
AB  - Stereotactic body radiotherapy (SBRT) for centrally-located lung tumors remains a 
      challenge because of the increased risk of treatment-related adverse events 
      (AEs), and uncertainty around prescribing the optimal dose. The present study 
      reported the results of central tumor SBRT with 56 Gy in 7 fractions (fr) at the 
      University of Tokyo Hospital. A total of 35 cases that underwent SBRT with or 
      without volumetric-modulated arc therapy consisting of 56 Gy/7 fr for central 
      lung lesions between 2010 and 2016 at the University of Tokyo Hospital were 
      reveiwed. A central lesion was defined as a tumor within 2 cm of the proximal 
      bronchial tree (RTOG 0236 definition) or within 2 cm in all directions of any 
      critical mediastinal structure. Local control (LC), overall survival (OS), and 
      AEs were investigated. The Kaplan-Meier method was used to estimate LC and OS. 
      AEs were scored per the Common Terminology Criteria for Adverse Events Version 
      4.0. Thirty-five patients with 36 central lung lesions were included. Fifteen 
      lesions were primary non-small cell lung cancer (NSCLC), 13 were recurrences of 
      NSCLC, and 8 had oligo-recurrences from other primaries. Median tumor diameter 
      was 29 mm. Eighteen patients had had prior surgery. At a median follow-up of 13.1 
      months for all patients and 18.3 months in surviving patients, 22 patients had 
      died, ten due to primary disease (4 NSCLC), while three were treatment-related. 
      The 1- and 2-year OS were 57.3 and 40.4%, respectively, and median OS was 15.7 
      months. Local recurrence occurred in only two lesions. 1- and 2-year LC rates 
      were both 96%. Nine patients experienced grade >/=3 toxicity, representing 26% of 
      the cohort. Two of these were grade 5, one pneumonitis and one hemoptysis. 
      Considering the background of the subject, tumor control of our central SBRT is 
      promising, especially in primary NSCLC. However, the safety of SBRT to central 
      lung cancer remains controversial.
FAU - Aoki, Shuri
AU  - Aoki S
AD  - Department of Radiology, University of Tokyo Hospital, Tokyo 113-8655, Japan.
FAU - Yamashita, Hideomi
AU  - Yamashita H
AD  - Department of Radiology, University of Tokyo Hospital, Tokyo 113-8655, Japan.
FAU - Haga, Akihiro
AU  - Haga A
AD  - Medical and Dentistry Laboratory, University of Tokushima, Tokushima 770-8501, 
      Japan.
FAU - Ota, Takeshi
AU  - Ota T
AD  - Department of Radiology, University of Tokyo Hospital, Tokyo 113-8655, Japan.
FAU - Takahashi, Wataru
AU  - Takahashi W
AD  - Department of Radiology, University of Tokyo Hospital, Tokyo 113-8655, Japan.
FAU - Ozaki, Sho
AU  - Ozaki S
AD  - Department of Radiology, University of Tokyo Hospital, Tokyo 113-8655, Japan.
FAU - Nawa, Kanabu
AU  - Nawa K
AD  - Department of Radiology, University of Tokyo Hospital, Tokyo 113-8655, Japan.
FAU - Imae, Toshikazu
AU  - Imae T
AD  - Department of Radiology, University of Tokyo Hospital, Tokyo 113-8655, Japan.
FAU - Abe, Osamu
AU  - Abe O
AD  - Department of Radiology, University of Tokyo Hospital, Tokyo 113-8655, Japan.
FAU - Nakagawa, Keiichi
AU  - Nakagawa K
AD  - Department of Radiology, University of Tokyo Hospital, Tokyo 113-8655, Japan.
LA  - eng
PT  - Journal Article
DEP - 20180723
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC6126178
OTO - NOTNLM
OT  - central lung tumor
OT  - lung cancer
OT  - pulmonary oligo-recurrence
OT  - radiation pneumonitis
OT  - stereotactic body radiotherapy
OT  - volumetric modulated arc therapy
EDAT- 2018/09/15 06:00
MHDA- 2018/09/15 06:01
PMCR- 2018/07/23
CRDT- 2018/09/15 06:00
PHST- 2018/02/03 00:00 [received]
PHST- 2018/07/03 00:00 [accepted]
PHST- 2018/09/15 06:00 [entrez]
PHST- 2018/09/15 06:00 [pubmed]
PHST- 2018/09/15 06:01 [medline]
PHST- 2018/07/23 00:00 [pmc-release]
AID - OL-0-0-9188 [pii]
AID - 10.3892/ol.2018.9188 [doi]
PST - ppublish
SO  - Oncol Lett. 2018 Oct;16(4):4498-4506. doi: 10.3892/ol.2018.9188. Epub 2018 Jul 
      23.